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Abstract. Gut microbiota have been studied in relation to the pathophysiology of Parkinson’s disease (PD) due to the early
gastrointestinal symptomatology and presence of alpha-synuclein pathology in the enteric nervous system, hypothesized to
ascend via the vagal nerve to the central nervous system. Accordingly, sixteen human case-control studies have published
gut microbiome composition changes in PD and reported over 100 differentially abundant taxa covering all taxonomic levels
from phylum to genus or species, depending on methodology. While certain findings were replicated across several studies,
various contradictory findings were reported. Here, differences in methodologies and the presence of possible confounders in
the study populations are assessed for their potential to confound the results of gut microbiome studies in PD. Gut microbiome
studies in PD exhibited considerable variability with respect to the study population, sample transport conditions, laboratory
protocols and sequencing, bioinformatics pipelines, and biostatistical methods. To move from the current heterogeneous
dataset towards clinically relevant biomarkers and the identification of putative therapeutic targets, recommendations are
derived from the limitations of the available studies to increase the future comparability of microbiome studies in PD. In
addition, integration of currently available data on the gut microbiome in PD is proposed to identify robust gut microbiome
profiles in PD. Furthermore, expansion of the current dataset with atypical parkinsonism cohorts, prodromal and treatment-
naı¨ve de novo PD subjects, measurements of fecal microbial concentrations and multi-omics assessments are required to
provide clinically relevant biomarkers and reveal therapeutic targets within the gut microbiome of PD.
Keywords: Parkinson disease, gut microbiome, case-control studies, systematic review
BACKGROUND
Parkinson’s disease (PD) is clinically defined as
a movement disorder characterized by motor symp-
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toms related to dopaminergic degeneration of the
substantia nigra [1]. Non-motor symptoms precede
the motor symptoms by years in a majority of cases
[2]. Different non-motor symptoms such as idiopathic
REM sleep behavior disorder (iRBD), hyposmia,
depression and constipation, are associated with an
increased risk of PD [3]. Combined, they can be
used to identify probable prodromal PD subjects
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with over 80% certainty [3]. The longest prodro-
mal period, up to 20 years, has been suggested for
constipation [4].
In concordance with the gastrointestinal symp-
tomatology, low grade inflammation and intestinal
barrier dysfunction has been reported in PD [5, 6].
Moreover, alpha synuclein (aSyn) deposition in Lewy
bodies and neurites, the pathological hallmark of PD,
is also found in the enteric nervous system (ENS) of
established and prodromal PD cases [7]. The synu-
cleinopathy is hypothesized to spread in a prion-like
manner via the vagal nerve. Accordingly, a protective
effect of truncal vagotomy for PD was established
in large epidemiological studies [8, 9]. Given the
early gastrointestinal dysfunction and pathology, the
gut could be a source organ for disease initiation
in PD.
In the last decade, non-targeted sequencing of
the gut microbiome or the bacterial and archaeal
community structure, using shotgun metagenomics
or 16S rRNA gene amplicon surveys respectively,
has become accessible to clinical researchers [10].
Changes in gut microbiome composition have been
described in various neurodegenerative disorders, of
which PD has been studied most extensively [11].
Besides the associative evidence from human case-
control studies, there is a substantial body of evidence
from animal models for a potential role of gut micro-
biota in the pathophysiology of PD [12, 13]. Notably,
Sampson et al. showed gut microbiota to regulate
the synucleinopathy, neuroinflammation and motor
impairments in a rodent PD model [12].
Despite the large societal impact of PD, the cause
of PD remains elusive and only symptomatic treat-
ments exists. In addition, the clinical diagnosis of
PD poses a clear diagnostic challenge and is rejected
in 20% of the cases [14]. There is furthermore a
need for biomarkers that would allow identification
of PD already in the prodromal period [15]. To fur-
ther elucidate the pathophysiological significance of
gut microbiome composition changes in PD and to
assess their potential as a marker for PD risk, diagno-
sis, stratification and prognosis, it is essential to assess
whether microbiome composition changes specific
for PD can be discerned. Here, a systematic review of
the currently available fecal gut microbiome compo-
sition studies in PD is provided, which are compared
based on their methodologies and results. To over-
come the current inconsistencies and move towards
clinical applications, recommendations are made to
increase the quality and comparability of future
microbiome studies in PD.
METHODS
Original studies published in peer-reviewed jour-
nals were searched in the PubMed database using
the search string “Parkinson” AND “Microbiome”
OR “Microbiota” OR “Dysbiosis” NOT “Review”.
Publications were included based on the follow-
ing criteria: Parkinson’s disease is the phenotype
of interest; Human case-control studies; Analysis
of gut microbiome composition; Use of fecal sam-
ples; Original microbiome data; Written in English.
Sixteen case-control studies concerning original gut
(fecal) microbiome data were identified, including
the recently accepted study by Aho et al., a follow-up
study on the first gut microbiome case-control cohort
in PD of Scheperjans et al. [16–31]. An overview
of the selection process of eligible publications is
provided in Fig. 1.
RESULTS
Study characteristics
Study populations varied in sample size from 10
to 197 PD subjects and 10 to 130 healthy con-
trol subjects (HC). All studies represented a total of
seven different countries. The mean age was similar
between the PD and HC groups for all studies except
for one study with a control group that was on average
fifteen years younger [25]. The proportion of females,
however, varied considerably between the PD and HC
groups in nine studies with at least ten percent dif-
ference, the highest difference being 34%. In three
studies, the samples were frozen immediately after
collection and remained frozen until DNA extrac-
tion. Other studies used either a nucleotide stabilizer
before freezing (n = 4), shipped the samples at ambi-
ent temperatures within a certain timeframe (n = 3),
shipped the samples on ice (n = 1) or did not report
on the sample shipment conditions before freezing
(n = 5). Almost all studies used different DNA extrac-
tion kits with only the PSP Stool DNA Plus Kit and
the QIAamp DNA Stool Mini Kit being used in mul-
tiple studies: four and two, respectively. Two studies
used targeted measurements of the abundance of
selected taxa, whereas all other studies used amplicon
sequencing. Of these, thirteen characterized the bac-
terial community structure, possibly supplemented
with the archaeal community structure, through 16S
rRNA gene sequencing, whereas one used shotgun
metagenomic sequencing to also include microbial
eukaryotes, viruses and bacteriophages. An overview
J.M. Boertien et al. / Review Microbiome in PD S299
Fig. 1. Overview of screening procedure to identify case-control gut microbiome studies in Parkinson’s disease.
of the study characteristics, including demographic
data and the procedures for sample collection, DNA
extraction and sequencing, is provided in Table 1.
Microbiome composition changes in PD
Differences in microbial community composition
can be described in terms of fecal microbial con-
centration, alpha and beta diversity, and relative
abundances in the form of sequence counts or propor-
tions. Microbial concentrations were reported in one
study, showing a decreased abundance of microbes
in the feces of PD compared to HC. Out of thirteen
studies using amplicon sequencing methods in orig-
inal study populations, alpha diversity indices were
reported in eleven studies of which three reported
higher alpha diversity in PD, six reported no differ-
ence, one reported lower alpha diversity in PD and
one did not report on the direction of the found dif-
ference. Beta diversity was reported in all studies that
performed 16S rRNA gene sequencing or metage-
nomic sequencing, all of which reported a difference
between PD and HC. An overview of the micro-
bial concentrations, alpha- and beta-diversity results
in fifteen original study populations is provided in
Table 2.
All studies found taxa that were differentially
abundant between PD and HC. Combined, over 110
differentially abundant taxa are described that cover
all taxonomic levels from phylum to species. In
particular, an increase in the relative abundances
of Verrucomicrobiaceae and Akkermansia, as well
as a decrease of Prevotellaceae were consistently
reported in nine, six and eight studies respectively.
An overview of the most frequently reported dif-
ferentially abundant taxa, mentioned in at least four
independent populations, is provided in Table 3.
In addition to case-control comparisons, eleven
studies assessed gut microbiome differences in rela-
tion to PD clinical variables, including clinical
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subtypes, disease duration and motor symptom
burden, of which disease duration had the most con-
sistent association with gut microbiome composition.
Notably, in the only follow-up study using ampli-
con sequencing in PD, beta diversity did not differ
between timepoints, but did differ between patients
and controls at both timepoints [30]. PD-associated
changes in microbiome composition therefore out-
weighed temporal intra-subject variability.
DISCUSSION
Since the first publication on gut microbiome dif-
ferences in PD by Scheperjans et al. [16], several
findings, such as an increase of Verrucomicrobiaceae
and Akkermansia, and a decrease of Prevotellaceae
were robustly replicated. Nonetheless, most findings
could not be replicated and various contradictory
findings were reported, hampering the extrapolation
to PD as a whole or to specific subtypes. Exam-
ples of frequently reported taxa with contradictory
results are Lactobacillaceae and Bacteroidetes. Four
studies reported a statistically significant increase of
Lactobacillaceae in PD, whereas two other report a
statistically significant decrease. Bacteroidetes were
significantly increased in one study, whereas two
other reported a significant decrease.
Though, to a certain degree, different findings
can be attributed to the inherent intra- and inter-
subject variability of gut microbiome composition
[32], methodological inconsistencies between gut
microbiome case-control studies in PD might con-
tribute to the heterogeneity of the results. Here,
differences in study population, sample collection,
laboratory procedures and sequencing of the fifteen
studies concerning original study populations are dis-
cussed and assessed for their potential to confound the
results of gut microbiome studies in PD.
Study population and assessments
Despite large differences in sample size, ranging
from 10 to 197 PD subjects, all studies reported sta-
tistically significant differences between PD and HC.
Nonetheless, the inability to replicate previous find-
ings could be attributed in some cases to the low
sample size of less than 50 PD subjects and controls
found in nine studies. On the contrary, the two largest
studies, with 193 and 197 PD subjects, also did not
replicate findings from previous studies. Other vari-
ables within the study population should therefore be
assessed for their confounding influence, including
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Table 3
Differentially abundant taxa between Parkinson’s disease patients (PD) and healthy controls (HC)
Phylum Family Genus Number of citations Increased abundance Decreased abundance
(statistically (statistically (statistically
significant) significant) significant)
Verrucomicrobia Verrucomicrobiaceae 9 (6) 9 (6) 0 (0)
Bacteroidetes Prevotellaceae 8 (3) 0 (0) 8 (3)
Firmicutes Lactobacillaceae 7 (6) 5 (4) 2 (2)
Verrucomicrobia Verrucomicrobiaceae1 Akkermansia 6 (6) 6 (6) 0 (0)
Actinobacteria Bifidobacteriaceae Biﬁdobacterium 6 (4) 5 (4) 1 (0)
Firmicutes Lachnospiraceae 6 (5) 1 (1) 5 (4)
Verrucomicrobia 5 (4) 5 (4) 0 (0)
Firmicutes Clostridiaceae Faecalibacterium 5 (3) 0 (0) 5 (3)
Bacteroidetes Prevotellaceae Prevotella 5 (1) 0 (0) 5 (1)
Proteobacteria Enterobacteriaceae 5 (4) 4 (4) 1 (0)
Firmicutes Lactobacillaceae Lactobacillus 5 (5) 4 (4) 1 (1)
Actinobacteria Biﬁdobacteriaceae 5 (3) 4 (3) 1 (0)
Firmicutes Lachnospiraceae Roseburia 4 (4) 0 (0) 4 (4)
Firmicutes Enterococcaceae 4 (4) 3 (3) 1 (1)
Firmicutes 4 (3) 1 (1) 3 (2)
Bacteroidetes 4 (3) 2 (1) 2 (2)
Firmicutes Erysipelotrichaceae 4 (3) 2 (2) 2 (1)
Firmicutes Ruminococcaceae 4 (1) 2 (1) 2 (0)
Overview of the most frequently reported differentially abundant fecal microbiota between PD and HC, found in at least four independent
populations. Reported taxa are mentioned in bold, with higher taxonomic levels (phylum and/or family) provided when applicable. Total
number of citations and the number of citations indicating an increased or decreased relative abundance in PD are mentioned respectively.
Number of publications reporting a statistically significant difference in relative abundance (P < 0.05) are mentioned between parentheses.
1Depending on the taxonomic nomenclature, Akkermansia can also be classified as a genus of the family Akkermansiaceae.
differences in geographical background, age and sex
distributions, PD disease status, medication use and
the occurrence of gastrointestinal determinants of gut
microbiome composition.
Geographical gut microbiome signatures may
prevent the extrapolation of phenotype associated
microbiome changes between populations from dif-
ferent geographical background [33, 34]. They can
therefore account for inter-study differences in the
microbiome studies in PD, as seven different coun-
tries are represented in the current dataset. Intra-study
geographical distributions, however, were adequately
addressed as each study recruited a control group
through either the same medical center or institutes
within the same area. Hill-Burns et al., the only study
that recruited from three distinct locations, reported
a statistically significant contribution of geographi-
cal site to gut microbiome composition changes in
PD that was adjusted for during modeling.
Age and sex are well-known determinants of gut
microbiome composition which are classical match-
ing criteria between case and control groups [35, 36].
In nine studies more than ten percent difference in the
proportion of females between the PD and HC group
is observed, with one study also reporting a differ-
ence in mean age of 15 years. A possible explanation
for these differences could be the inclusion of cohab-
itants or spouses as HC in at least six studies. Though
cohabitant or spousal controls might be more suitable
to adjust for environmental confounders, differences
in age and sex distribution should be accounted for as
potential confounders in all case-control gut micro-
biome studies. Age and sex differences were only
incorporated as covariates in seven studies. Due to
inadequate matching in various studies and the lack of
post-hoc correction, age and sex effects could there-
fore possibly contribute to the heterogeneity of results
between microbiome studies in PD.
PD is a heterogeneous disorder with varying
clinical presentations that might represent different
etiologies [37]. The clinical variability of PD was
addressed in nine studies by adding disease duration
or symptom severity as a covariate, or by analyzing
different PD subtypes within the PD cohort. Eight
studies could correlate microbiome signatures to PD-
related clinical variables, most often disease duration,
despite a further reduction of statistical power. In
particular, Barichella et al. reported beta diversities
to become more distant between PD and HC as the
disease progresses. To date, two longitudinal follow-
up microbiome studies in PD have been performed
[30, 38]. Minato et al., a two year follow-up study of
the subjects from the Hasegawa et al. study, reported
differences in selected taxa over time, suggesting
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that the gut microbiome composition of PD subjects
changes with disease duration [38]. On the contrary,
Aho et al. found no differences in microbial commu-
nity structure in both cases and controls after a similar
follow-up period [30]. Possibly, the follow-up period
of a little over two years in Aho et al. is too short
to reveal temporal changes as the disease progresses,
whereas Barichella et al. describe microbiome com-
position in relation to the large variation in disease
duration observed in their cross-sectional sample of
zero to 25 years. Therefore, differences in PD clinical
status could explain part of the non-replicated results
in PD microbiome studies, as microbiome shifts in
PD might become more distinct as the disease pro-
gresses.
Besides clinical features, various genetic variants
have been described to increase the risk of PD,
possibly accentuating different parts of PD etiology
with varying degrees of gastrointestinal involvement
[39]. Also, different genome wide association studies
(GWAS) have identified genetic variants as deter-
minants of microbiome composition, regardless of
PD status [40–42]. Genetic drift and founder effects
can lead to different genetic backgrounds in differ-
ent populations [43]. Various microbiome studies
in PD have attempted to limit the influence of the
genetic background through the exclusion of sub-
jects with a positive family history and/or age of onset
below 50 years. However, most PD associated vari-
ants only increase the disease risk by a few percent
and can be present without a positive family his-
tory. Only Barichella et al. screened for mutations in
one PD associated gene (Parkin), found in two sub-
jects. No microbiome study in PD assessed the host
genome on a genome wide scale, including possible
genetic determinants of gut microbiome composi-
tion. Therefore, differences in genetic background
could potentially explain inter-study differences of
the current PD microbiome results.
To date, the effect of dopaminergic medication
on gut microbiome composition has not been stud-
ied directly. Nonetheless, the effect of dopaminergic
medication can be hypothesized to be substantial,
as effects of various medications on gut microbiota
composition have been described [17, 35, 36]. Most
microbiome case-control studies in PD concern a
cross-sectional sample of already treated PD sub-
jects. Although five studies adjusted for the effects
of medications that were differentially prescribed
within their PD cohort, or tried to link micro-
bial effects to the Levodopa Equivalent Daily Dose
(LEDD), the one-sided introduction of dopaminer-
gic medication as a possible confounder hinders
the interpretation of the current microbiome data in
PD. Bedarf et al. introduced a cohort that is Lev-
odopa naı¨ve. However, all PD subjects were treated
using other dopaminergic drugs. Contrary to other
publications, no effect from differentially prescribed
dopaminergic drugs was reported by Bedarf et al.
which the authors attribute to the small sample size
of the study. Keshavarzian et al. and Barichella
et al. included 12 and 39 treatment-naı¨ve PD subjects
respectively. Keshavarzian et al. found a difference
in microbiome composition between untreated and
treated PD subjects, but attributed this to differences
in disease duration. Barichella et al. report a lower
Lachnospiraceae abundance in untreated PD com-
pared to HC, which was not found in treated subjects.
Another treatment-naı¨ve sample can be derived from
Heintz-Buschart et al. who included 20 polysomnog-
raphy (PSG) proven iRBD patients as prodromal
PD [2]. Compared to HC, 41 operational taxonomic
units (OTUs) were differentially abundant in iRBD
of which over 75% showed a similar change as was
found in their PD cohort compared to HC. Nonethe-
less, the extent to which the remaining 25% can be
attributed to medication effects, the temporal changes
as the disease progresses or a distinct RBD pos-
itive clinical subtype, remains to be seen. Larger
gut microbiome studies in treatment-naı¨ve PD sub-
jects are therefore required to distinguish medication
effects from disease specific changes in gut micro-
biome composition.
A variety of gastrointestinal determinants of gut
microbiome composition have been identified in
population-based cohort studies, including gastroin-
testinal disease and/or surgery, constipation, and
dietary influences [35, 36]. First, gastrointestinal
disease and/or surgery were used as exclusion cri-
teria in the microbiome studies in PD with varying
stringency. Second, constipation is a known determi-
nant of gut microbiome composition and a common
non-motor symptom in PD, with objective measures
revealing a prolonged stool transit time in up to
80% of patients [35, 36, 44, 45]. No direct com-
parison with idiopathically constipated subjects was
performed. However, constipation was assessed in
five microbiome studies in PD using questionnaires
or an interview, which can underestimate its preva-
lence [44]. Where the most objective measurement,
using radio-opaque markers [44], can be unattainable
for large-scale microbiome studies, more objective
measurements of stool frequency and consistency
can be obtained through a stool diary and the Bris-
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tol Stool Chart [45, 46]. Also, moist content of
the fecal sample can be used as a marker for stool
transit time and consistency [47]. Last, various
nutrients exert an influence on gut microbiome com-
position [35, 36]. Dietary habits were included as
covariate in five studies, with different emphasis such
as protein consumption and fruit-vegetable consump-
tion. To minimize recall bias and provide a complete
assessment of nutrient intake, food diaries can be used
in combination with food frequency questionnaires
to obtain more reliable and complete information on
dietary habits [48].
Sample collection, transport, and storage
Sampling procedures can introduce bias during
sampling itself or during transportation and storage
[49, 50]. During sampling, contact with urine and
toilet water should be avoided to not dilute and con-
taminate the sample. Commercially available paper
fecal collectors minimize the risk of contact of urine
and water with the stool. Not all studies reported the
usage of a fecal collector, but it can be assumed that
all studies used similar collectors, as a fecal micro-
biome study would otherwise become too impractical
for most participants, in particular PD subjects who
might have impaired fine motor skills. Correct usage
of the collector was not assessed by means of, for
instance, questionnaires, nor were samples assessed
for moist content in relation to stool type to red flag
possibly contaminated samples.
Continued differential growth of microbes dur-
ing transportation and storage can introduce artificial
differences [51]. When frozen, microbiome com-
position remains stable for a few months at –20 C
and up to two years at –80 C [51]. Ideally, sam-
ples should be frozen within 48 hours when stored
at 4◦C or within four hours when stored at ambient
temperatures [51]. Compared to the “gold standard”
of immediate freezing, various preservatives have
been assessed, most of which adequately prevent
microbial composition shifts for one week [50]. How-
ever, RNAlater is an example of a preservative that
less adequately prevents microbiome composition
shifts, which in particular hampers the analysis of
rare taxa [52]. An additional issue is the ease with
which the preservative can penetrate the sample,
which is dependent on the size of the sample and
the stool consistency [51], the latter being firmer
in PD subjects who often suffer from constipa-
tion [44]. The microbial shifts found when using
a preservative are, however, small compared to
the temporal intra-subject microbiome variation and
inter-subject variability [32]. Nonetheless, not imme-
diately freezing the samples can potentially introduce
biases.
From the fifteen PD microbiome studies in original
populations, only three immediately froze the sam-
ple, whereas others transported the sample on ice,
used a preservative or shipped the sample at ambient
temperatures. Five studies did not report the use of
a preservative and/or the transportation conditions.
Only Hill-Burns et al., who shipped samples with-
out preservative at ambient temperatures, reported
on sample shipping time [17]. Shipping time was
identified as a significant contributor to microbiome
composition changes, which was adjusted for during
modeling [17]. Inadequate adjustment for microbial
shifts due to sample transportation conditions can
therefore be a potential source for both intra- and
inter-study differences.
Laboratory procedures
All phases during the library preparation, from
DNA extraction to sequencing, can potentially intro-
duce bias through differences in reagent quality,
usage of different kit production batches during the
same project, changes to protocols and/or lab person-
nel during the project, and contamination between
batches [51, 53]. Various DNA extraction kits are
available for fecal samples that rely on chemical
lysis, possibly in combination with mechanical lysis
[51]. Different lysis methods yield different microbial
DNA based on the effectiveness with which the cell
wall can be broken down [51]. Besides the method
of lysis, which will be the same for case and con-
trol samples in studies, contamination of reagents can
introduce batch effects that might drive artificial dif-
ferences between PD and HC [53]. Most notably in
this respect is the paper by Salter et al. who analyzed a
blank control parallel to a pure culture of Salmonella
bongori using four widely used DNA extraction kits,
three of which were used in microbiome studies in PD
[53]. All kits showed contamination, which led to the
notion of a “kitome” that should be corrected for [51].
This kitome might also differ between kits from the
same manufacturer depending on production batch
and laboratory procedures. As DNA extraction of all
case and control samples together in a single batch
using the same DNA extraction kit and manufactur-
ing batch is often not feasible, Salter et al. provide
concrete recommendations to mitigate the risk and
effects of reagent contamination. They suggest the
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use of high biomass samples to avoid a predominant
effect of the contaminants; to use technical controls
for each DNA extraction and PCR kit; and to random-
ize samples both before DNA extraction and library
preparation for sequencing, to avoid batch effects
[53]. Failure to do so might lead to misleading results
that represent technical batch effects that can exceed a
biological effect and should be corrected for in silico
[53].
At least ten different DNA extraction kits were
used in the microbiome studies in PD, that deployed
different methods of chemical and mechanical lysis,
with some only relying on chemical lysis. Different
yields for different microbes might contribute to the
heterogeneity of results between studies. In addition,
only Heintz-Buchart and the follow-up of Scheper-
jans et al. by Aho et al. reported the implementation
of the recommendations made by Salter et al. [26, 30]
Instead of mere inter-study differences due to a dif-
ferent scope resulting from lysis efficiency, this might
introduce artificial results that do not reflect any PD
related effect and can potentially lead to contradictory
results between studies.
Sequencing
The scope of the microbiome studies in PD is pri-
marily determined by the sequencing method and
can be divided into three groups. Hasegawa et al.
and Unger et al. resorted to direct quantification of
selected microbes which obviously limits the scope
to the selected taxa. Only Bedarf et al. used shot-
gun metagenomic sequencing which is based on
all available DNA fragments and therefore includes
microbial eukaryotes and viruses besides bacteria
and archaea [10]. All other studies sequenced one
or more of the variable regions of the 16S rRNA
gene which evolutionary conservation is often used
for the taxonomic classification of bacteria and can
also be used to classify archaea if dedicated primers
are used [10]. Minor variations in the discrimina-
tive power of the variable regions exist, but do not
exceed inter-individual variance [54]. The possibility
of bias introduced by sequencing different variable
regions is further reduced as only two out of thir-
teen studies using 16S sequencing did not include
the V4 variable region. Nonetheless, different dis-
criminative abilities between the variable regions and
PCR primers could account for failed replication of
specific taxa, especially on lower taxonomic levels
[55]. Non-replication of differences in the abun-
dance of Bifidobacteria can for instance be attributed
to the different variable regions used and primer
choice [55]. Notably, Aho et al. picked up differences
in Bifidobacteria abundance when resequencing the
baseline samples of Scheperjans et al. using the V3-
V4 variable regions rather than V1-V3 [30].
With the exception of Hasegawa et al. and Unger
et al., all microbiome studies in PD report on
microbial abundances relative to the abundance of
other microbes. Though relative microbiome profil-
ing (RMP) is common practice in microbiome studies
across phenotypes, the biological interpretation is
limited without information on the fecal concentra-
tion of microbes [47]. For instance, a direct influence
of fecal microbial concentration on the phenotype
of interest is neglected and no accurate estimates of
metabolite concentrations can be made [47]. More-
over, Vandeputte et al. showed how fecal microbiome
concentrations are a determinant of microbiome
diversity and suggest the use of flowcytometry and/or
qPCR of the 16S rRNA gene to adjust for the con-
founding effect of fecal microbiome concentrations
[47]. Only one microbiome study in PD reported
on the fecal microbial concentration, showing a
decreased concentration of microbes in the feces.
Fecal microbiome concentrations could therefore
introduce an unexplored bias between PD and HC.
Increasing comparability of microbiome studies
in PD
Microbiome studies are notorious for the large
variety of methodologies [51]. Gut microbiome stud-
ies in PD are no exception, as different methodologies
were found in all phases, including sample collection,
laboratory procedures, sequencing and adjustment
for confounders within the study populations. An
overview of the differences in study populations
and methodologies between gut microbiome stud-
ies in PD is provided in Fig. 2. Although technical
differences might introduce bias, practical consider-
ations to obtain sufficient sample size can justify the
deviation from “gold standard” practices. Here, the
potential confounding effects of various technical,
phenotypical and environmental determinants of gut
microbiome composition were assessed. From this,
recommendations can be derived to standardize and
increase the utility of future microbiome studies in
PD, which are listed in Box 1.
In parallel, integration of the currently available
microbiome data in PD would allow for the discov-
ery of robust microbial associations and confounder
adjustment necessary to address the current vari-
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Fig. 2. Differences in study populations and methodologies between gut microbiome studies in Parkinson’s disease (PD). (a) Study popu-
lations differed in age and sex distributions, sample size, geographical background, and the extent to which gastrointestinal confounders of
gut microbiome composition were assessed. (b) Differences in PD subtypes, disease duration and PD medication regimen were linked to gut
microbiome composition changes. (c) Sample collection procedures, transport conditions, DNA extraction, sequencing and the analytical
and bio-informatics pipelines are known technical confounders of gut microbiome composition studies and differed across gut microbiome
studies in PD. TD, tremor dominant subtype; AR/PIGD, akinetic rigid and/or postural instability and gait disorders subtypes; HC, healthy
controls.
ability of the results. Currently, a meta-analysis of
differentially abundant taxa in PD is hampered by
the lack of descriptive statistics and an overem-
phasis on statistically significant results, ignoring
the effect estimates of previously reported taxa. To
adequately assess effect sizes and their respective
degree of uncertainty, results on differentially abun-
dant taxa should include all previously reported taxa,
regardless of effect size or statistical significance.
Nonetheless, the variety of bioinformatic and analyt-
ical tools used in microbiome studies can still impact
inter-study comparability due to different annota-
tion pipelines, clustering cut-offs and compositional
metrics, as well as statistical methods. Ideally, raw
sequencing data should be made publicly available
to aid meta-analyses using standardized analytical
pipelines. A meta-analysis of sequencing data from
different variable regions of the 16S rRNA gene is
possible through closed-reference operational taxo-
nomic unit (OTU) picking [54]. Even though this will
not resolve differences in the resolution of the vari-
able regions, the predominant use of the V4 region
in twelve out of fourteen 16S studies in PD, includ-
ing the re-sequenced baseline samples of Aho et al.,
increases the inter-study comparability. More impor-
tantly, the increase in sample size would allow for
more robust conclusions on the gut microbiome com-
position of PD subjects: a total sample size of 874
PD and 665 HC subjects could be achieved through
integration of the raw sequencing data of all PD
microbiome studies using 16S sequencing data. In
addition, disclosure of per sample technical, pheno-
typical and environmental data would aid adjusting
for confounders that could possibly not be adjusted
for within a given study due to low sample size. As
public availability of subject information might be
restricted due to privacy and confidentiality legis-
lation, sample metadata can still be made available
upon request. Currently, seven studies have made
their raw sequencing data publicly available.
Towards gut microbial biomarkers for PD
Exploitation of gut microbiome changes for early
PD diagnosis or as a possible prognostic marker is
not only dependent on standardization of case-control
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Box 1
Recommendations to increase the comparability and utility of (gut) microbiome studies in PD
Technical aspects:
• Include information on transport and storage conditions (temperatures, time and use of preservatives) if samples are not
immediately frozen after collection.
• DNA extraction, library preparation and sequencing should ideally be performed for all samples in one run.
Randomization of samples before each step and batch annotation should be performed to correct for batch effects.
• Multiple sequencing runs can be performed with all biological samples included per run, after which the total sequence
data can be merged per sample.
• Negative controls should be analyzed for each batch during DNA extraction, library preparation and sequencing to
adjust for contamination. Ideally, replicates of samples should be present in different batches.
• 16S sequencing should include the V4 variable region to assure maximum compatibility with previous studies.
• Microbial concentrations of samples should be reported to allow for quantitative microbiome profiling.
Phenotypical and environmental confounders:
• Age and sex
• PD subtype and disease duration
• Use of medication
• Host genome
• Gastrointestinal disease and/or surgery
• Stool frequency and consistency, possibly supplemented with moist content of the fecal sample
• Dietary habits by means of a food diary
Study populations of particular interest:
• Treatment-naïve de novo PD subjects
• Atypical parkinsonism and other differential diagnoses of PD as control group
• Prodromal syndromes (e.g., iRBD)
studies and the integration of data to achieve sufficient
sample sizes to identify robust markers of disease.
Different practical applications require different con-
trol settings and study cohorts. Moreover, clinical
applications will likely depend on rapid quantifica-
tion of selected taxa.
The clinical diagnosis of PD poses a diagnos-
tic challenge with a rejection rate of up to 20%
[14]. In particular, multiple system atrophy (MSA),
progressive supranuclear palsy (PSP), corticobasal
degeneration (CBD), secondary parkinsonism, vas-
cular parkinsonism, essential tremor and dystonic
tremor are differential diagnoses that can be dif-
ficult to differentiate from idiopathic PD [56]. To
increase diagnostic accuracy, physicians can resort to
MRI to exclude other diagnoses (e.g., PSP, vascular
parkinsonism and ferrinopathies) or use FDOPA-
PET or DAT-SPECT to exclude patients with scans
without evidence of dopaminergic deficit (SWEDDs)
such as dystonic tremor [56]. Nonetheless, PD diag-
nosis is still rejected in up to 10% of cases in
specialized movement disorder clinics based on
insufficient response to chronic dopaminergic ther-
apy, rate of progression or autopsy [14]. Especially,
atypical parkinsonisms that still exhibit some dopa-
responsiveness (e.g., MSA) can be misclassified as
idiopathic PD despite a positive FDOPA-PET or
DAT-SPECT [56]. To avoid unnecessary treatment
and adequately inform patients about their disorder
and the associated prognosis, there is still a large need
for early diagnostic markers of PD. To assess the diag-
nostic potential of gut microbiome changes in PD, the
comparison with healthy age- and sex-matched con-
trols is insufficient. Ideally, gut microbiome changes
should be compared to imaging modalities for their
ability to differentiate between PD and related
disorders.
To date, two studies reported on microbiome
changes in atypical parkinsonisms. Engen et al. com-
pared the fecal microbiome of 6 MSA patients to 11
HCs and reported increased relative abundances in
MSA of Bacteroidetes, Clostridiaceae and Rikenel-
laceae, whereas the relative abundances of Firmicutes
and Coprobacillaceae were reduced [57]. Barichella
et al. included 22 MSA patients and 22 PSP patients
in their study next to 193 PD subjects and 113 HCs,
allowing for a first direct comparison between PD and
other neurodegenerative disorders [18]. Contrary to
PD, MSA and PSP subjects were not characterized
by higher alpha-diversity. Microbiome compositions
were also different between PD on the one hand and
PSP and MSA on the other hand in terms of beta-
diversity. Due to the small sample size, the authors did
not report extensively on taxonomic differences that
were directly assessed between the disorders. How-
ever, the increased levels of Lactobacillaceae in PD
compared to HC were also observed in MSA, but
not in PSP. Given the lower prevalence of atypical
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parkinsonisms and other PD mimicking syndromes
[58], the public availability of data becomes even
more important to obtain a large enough sample size
to allow robust adjustment for various potential con-
founders that could not be addressed in the current
studies. A meta-analysis comparing the various dis-
orders, as has been performed for other phenotypes
[59], would allow for an assessment of the discrimi-
native power of gut microbial signatures between PD
and associated disorders.
Next to the need for relevant control cohorts,
treatment-naı¨ve de novo PD subjects are required to
validate gut microbial biomarkers for the diagnosis
of PD. Barichella et al. showed less pronounced tax-
onomic differences between treatment-naı¨ve de novo
PD subjects and HC compared to already treated
subjects. Only a statistically significant reduction
in Lachnospiraceae was reported, whereas various
decreased an increased taxa were reported in already
treated subjects. Besides the lower sample size of
untreated subjects, this could be attributed to the
unexplored effect of dopaminergic medication on
gut microbiome composition. Disease duration, as a
known determinant of microbiome composition in
PD, obviously varied considerably between de novo
and already treated subjects. To adequately reflect the
context of PD diagnostics, gut microbiome studies
in untreated or recently treated patients in the early
phase of the disease are required.
Microbial changes to differentiate PD and its
subtypes from other clinical entities can vary in com-
plexity from different quantities of specific taxa or
metabolites to complex microbial signatures. Current
microbiome study procedures are time consuming
and require extensive and specialized bioinformatic
and statistical expertise [10]. Clinical applications of
microbiome signatures will therefore ideally rely on
rapid quantification of selected taxa using established
methods such as qPCR. To facilitate the shift from
microbiome studies based on relative abundance to
clinically applicable quantification methods, micro-
biome studies should report on the fecal microbial
concentration of samples through for instance flow
cytometry or qPCR of the 16S rRNA gene [47].
From this, taxa of interest can be quantified using
the already available data [47].
Towards gut microbial interventions in PD
To move towards gut microbial interventions in
PD, integration of gut microbiome data in PD can
aid the identification of putative causative or protec-
tive microbes by means of mendelian randomization
(MR) [60]. Moreover, expansion of microbiome data
with a multi-omics assessment will provide insight
into microbiome-host interactions in PD [61].
MR leverages genetically determined variance of
a given exposure to establish causality between
a phenotype and the epidemiologically associated
exposure [60]. Using a two-sample MR study, causal
relationships between the abundance of microbial
taxa (exposure) and PD (phenotype) can be inferred
given two prerequisites. First, a strong epidemio-
logical association between specific taxa and PD
should be established, possibly through integration of
currently available microbiome data in PD. Second,
the influence of host genetics on the abundance of
specific taxa should be established in genome wide
association studies (GWAS). Three GWAS studies
have identified genetic variants in the lactase gene
(LCT) locus associated with gut microbiome com-
position changes [40–42]. Currently, the MiBioGen
consortium is an international initiative to expand the
current genome-microbiome associations by means
of a meta-analysis of 18 genome-microbiome stud-
ies that combined have around 19.000 participants
[54]. The establishment of well-powered genome-
microbiome associations and the integration of gut
microbiome studies in PD could be leveraged to indi-
cate putative causal microbiota in PD.
Expansion of the current data-set with multi-omics
assessments allows for a functional interrogation
of microbiome-host interactions [61]. These could
include metagenomic, metatranscriptomic, metapro-
teomic and metabolomic assessments [61], as well
as parallel sampling using glycerol embedded tubes
for large-scale culturing of microbes [62]. Currently,
only Bedarf et al. preformed shotgun metagenomics
sequencing in PD subjects. Contrary to 16S sequenc-
ing, where pathway annotation can only be performed
indirectly based on the putative metabolic arsenal
of a given taxon, shotgun metagenomic sequenc-
ing data can be correlated directly to genes and
their biological function next to taxonomic correla-
tion. Interestingly, Wang et al. derived biosynthetic
gene clusters (BGCs) from the Bedarf et al. metage-
nomics data and found 43 enriched BGCs of which 14
could not be correlated to differences in source taxa
between PD and HC [63]. Metagenomic sequencing
therefore transcends 16S sequencing in its poten-
tial to identify biological pathways that might be of
relevance for PD pathophysiology. Nonetheless, the
lack of expression data limits the interpretation of
metagenomic data, as no fecal metatranscriptomics
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or metabolomics study in PD has been performed to
date. Augmentation of metagenomic sequencing with
metatranscriptomics and/or metabolomics in a multi-
omics approach would further improve insight in the
metabolic consequences of microbiome composition
shift in the context of PD pathophysiology.
Putative causal relationships, derived from data
mining efforts of gut microbiome studies in PD,
should still be assessed for their pathophysiological
implications in relation to other determinants of the
enteric pathology in PD, including intestinal wall per-
meability, inflammation, alpha-synuclein aggrega-
tion and gastrointestinal dysfunction. Mucosal micro-
biome composition was assessed by Keshavarzian et
al. using sigmoid biopsies and revealed less marked
differences compared to fecal samples, indicating
not all differently abundant taxa in feces to interact
with the intestinal mucosa [25]. To reveal relevant
interactions in the multifactorial pathogenesis of PD,
integration of various determinants of the enteric
pathology in PD can be achieved using human intesti-
nal organoids (HIOs), besides regularly used in vitro
and preclinical models [64]. HIOs are 3D cellular
models of the human intestine established through
differentiation of induced pluripotent stem cells,
which can be reprogrammed from patient-derived
material [64]. Co-culture with enteric nervous system
tissue and gut microbiota allows for a patient specific
integrative assessment to elucidate significant contri-
butions of gut microbiota to the pathophysiology of
PD and reveal putative therapeutic targets [65, 66].
Conclusion
In light of the possible etiological implications
of gut microbiota in PD, microbiome data in PD
has rapidly accumulated in the past few years.
Several findings could be replicated in various stud-
ies, such as an increase of Verrucomicrobiaceae
and Akkermansia, and a decrease of Prevotellaceae.
However, there is currently no consensus on PD
specific changes in microbiome composition and
their pathophysiological implications due to incon-
sistent results, differences in methodologies and
unaddressed confounders. Standardization of study
protocols and the collection and publication of possi-
ble confounders and results, regardless of statistical
significance within one’s own dataset, could lead to
the homogenization of results needed to identify rel-
evant taxa. In this respect, public availability of raw
sequencing data and sample metadata would allow
for an integrative dataset of PD microbiome stud-
ies that could address various possible confounders.
Expansion of the current dataset with atypical parkin-
sonisms, prodromal and treatment-naı¨ve de novo PD
subjects, quantitative data on fecal microbial con-
centration and multi-omics assessments are required
to provide clinically relevant biomarkers and reveal
therapeutic targets within the gut microbiome of
PD.
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